Company
Every investor coverage indicates participated in a round Contraline raised.
Companies Contraline acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Kevin Eisenfrats | CEO | TechCrunch Australia |
Stories naming Contraline. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Male contraceptive startup Contraline has secured $7.2 million in a GV-led round to progress first-in-human trials of its ADAM hydrogel implant, with initial patients treated in Australia.